Peptide library / Brain & sleep / Davunetide
Davunetide
An eight amino acid peptide from activity-dependent neuroprotective protein, tested in a rare dementia.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Progressive supranuclear palsyLarge trials
- Mild cognitive impairmentSmall human studies
How it is thought to work
Davunetide was designed to stabilise microtubules in nerve cells, which are disrupted in tauopathies.
What the evidence shows
A phase 2 and 3 trial in progressive supranuclear palsy did not show benefit on disease progression.
Safety and unknowns
Nasal irritation was the main side effect.
Regulatory status
Not approved. Development stopped after the trial.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Brain & sleep
Delta sleep-inducing peptide
Wellness and performanceA nine amino acid peptide first isolated from rabbit brain in the 1970s and tested for insomnia.
Dihexa
Wellness and performanceAn experimental memory-enhancing compound derived from angiotensin IV, tested only in animals.
Cortexin
Wellness and performanceA polypeptide extract from calf brain cortex used in Russia after brain injury and in children with delays.
General information, not medical advice. Do not buy or inject unregulated peptides.